Alendronate Sodium
The sodium salt form of alendronic acid, a bisphosphonate medication that prevents bone breakdown by inhibiting osteoclast cells responsible for bone resorption. It is widely used to treat and prevent osteoporosis in postmenopausal women and men, and to treat Paget's disease of bone, significantly reducing the risk of fractures.
الوزن الجزيئي
325,1200 g/mol
TPSA
167,00 Ų
المجالات العلاجية
آلية العمل
Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.
البنية ثنائية الأبعاد
Cite this structure
Embed this structure
SMILES
NCCCC(O)(P(=O)([O-])O)P(=O)(O)O.[Na+]
InChI
InChI=1S/C4H13NO7P2.Na/c5-3-1-2-4(6,13(7,8)9)14(10,11)12;/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12);/q;+1/p-1
Molecular Formula
C4H18NNaO10P2
HBD / HBA
8 / 11
الروابط القابلة للدوران
5
الذرات الثقيلة
18
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
الأسئلة الشائعة
The sodium salt form of alendronic acid, a bisphosphonate medication that prevents bone breakdown by inhibiting osteoclast cells responsible for bone resorption. It is widely used to treat and prevent osteoporosis in postmenopausal women and men, and to treat Paget's disease of bone, significantly reducing the risk of fractures.
Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.
Yes, Alendronate Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL675. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 23681107. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="alendronate-sodium"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/alendronate-sodium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/alendronate-sodium/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/alendronate-sodium/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="alendronate-sodium"></drugfyi-drug>